Camber Launches Pomalidomide Capsules
Camber Pharmaceuticals continues to expand its portfolio of treatment options with the launch of Pomalidomide Capsules [pom-a-LID-oh-mide], generic for Pomalyst®.
Pomalidomide capsules are available in 1 mg, 2 mg, 3 mg, and 4 mg strengths in bottles of 21 capsules.
As part of Camber’s initiative to supply accessible, affordable medicine, Pomalidomide Capsules are backed by a copay program.
Pomalidomide Capsules are a REMS product that requires distributors to be enrolled in the corresponding REMS program.
To learn more about the Pomalidomide Capsules REMS program, click here.
Recent articles
- Camber Specialty Marks First Day 1 Injectable Launch
- New to Camber’s Portfolio: Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets
- Camber Pharmaceuticals Honored as Second Merit Finalist at 2026 DIANA Awards
- Camber Launches Nitazoxanide Tablets
- Cisatracurium Besylate Injection, USP Added to Camber’s Portfolio
- Camber Welcomes Summer 2026 Intern Class






